Patient demographics and baseline characteristics
| Quartile by anti-CCP2 concentration (AU/mL) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CCP2 negative | Q1, 28–235 | Q2, 236–609 | Q3, 613–1046 | Q4, 1060–4894 | ||||||
| Characteristic | ABA (n=66) | ADA (n=54) | ABA (n=42) | ADA (n=55) | ABA (n=51) | ADA (n=46) | ABA (n=46) | ADA (n=51) | ABA (n=46) | ADA (n=51) |
| Age, years | 52.0 (24.0, 80.0) | 58.0 (21.0, 83.0) | 50.0 (22.0, 70.0) | 50.0 (19.0, 78.0) | 52.0 (21.0, 78.0) | 49.0 (22.0, 73.0) | 47.5 (25.0, 73.0) | 52.0 (26.0, 78.0) | 51.5 (19.0, 70.0) | 52.0 (27.0, 85.0) |
| Female, % | 84.8 | 85.2 | 88.1 | 83.6 | 80.4 | 87.0 | 82.6 | 80.4 | 78.3 | 72.5 |
| White, % | 92.4 | 83.3 | 88.1 | 87.3 | 72.5 | 69.6 | 71.7 | 74.5 | 76.1 | 68.6 |
| Geographic region, % | ||||||||||
| North America | 86.4 | 90.7 | 71.4 | 63.6 | 70.6 | 67.4 | 65.2 | 60.8 | 52.2 | 64.7 |
| South America | 13.6 | 9.3 | 28.6 | 36.4 | 29.4 | 32.6 | 34.8 | 39.2 | 47.8 | 35.3 |
| MTX dose at randomisation, mg/wk | 15.0 (7.5, 105.0) | 18.8 (7.5, 25.0) | 20.0 (10.0, 25.0) | 15.0 (7.5, 105) | 15.0 (7.5, 25.0) | 15.0 (7.5, 25.0) | 15.0 (12.5, 25.0) | 15.0 (10.0, 25.0) | 15.0 (7.5, 25.0) | 15.0 (7.5, 25.0) |
| Smoking status, % | ||||||||||
| Current | 27.3 | 13.0 | 21.4 | 25.5 | 31.4 | 21.7 | 32.6 | 25.5 | 23.9 | 27.5 |
| Former | 21.2 | 29.6 | 14.3 | 20.0 | 15.7 | 19.6 | 10.9 | 17.6 | 34.8 | 15.7 |
| Never | 51.5 | 57.4 | 64.3 | 54.5 | 52.9 | 58.7 | 56.5 | 56.9 | 41.3 | 56.9 |
| Disease duration, years | 1.0 (0.1, 4.6) | 1.3 (0.0, 4.7) | 1.8 (0.2, 4.5) | 1.6 (0.1, 5.1) | 1.7 (0.1, 5.1) | 1.2 (0.1, 4.5) | 1.8 (0.1, 4.8) | 1.7 (0.1, 5.1) | 2.0 (0.1, 4.8) | 1.4 (0.0, 5.0) |
| Physical function, HAQ-DI | 1.3 (0.0, 2.9) | 1.4 (0.0, 2.6) | 1.4 (0.0, 2.5) | 1.3 (0.0, 2.5) | 1.7 (0.0, 2.8) | 1.6 (0.0, 2.9) | 1.4 (0.0, 2.8) | 1.6 (0.0, 3.0) | 1.6 (0.0, 2.9) | 1.8 (0.0, 2.8) |
| CRP (mg/dL) | 0.6 (0.0, 10.4) | 0.6 (0.0, 42.2) | 0.8 (0.1, 8.4) | 0.6 (0.0, 4.8) | 0.9 (0.0, 9.4) | 1.3 (0.1, 5.8) | 0.9 (0.1, 11.3) | 1.0 (0.0, 9.0) | 0.9 (0.0, 13.9) | 0.7 (0.0, 11.8) |
| DAS28 (CRP) | 5.5 (2.5, 7.4) | 5.3 (3.0, 7.3) | 5.0 (3.1, 7.6) | 5.5 (3.1, 7.3) | 5.6 (3.5, 7.6) | 6.0 (2.8, 7.4) | 5.5 (2.8, 8.1) | 5.7 (3.7, 7.9) | 6.0 (2.7, 7.8) | 5.3 (1.7, 7.8) |
| RF positive, % | 42.4 | 51.9 | 85.7 | 92.7 | 98.0 | 93.5 | 100.0 | 96.1 | 95.7 | 100.0 |
| RF concentration, U/mL | 4.7 (0.0, 368.6) | 6.1 (0.1, 388.3) | 119.5 (1.3, 500.9) | 137.5 (0.4, 500.9) | 225.6 (2.0, 500.9) | 270.9 (3.6, 500.9) | 298.9 (14.0, 500.9) | 266.9 (3.1, 500.9) | 377.1 (2.0, 500.9) | 351.0 (7.7, 500.9) |
| Total score (X-ray) | 3.5 (0.0, 86.5) | 6.5 (0.0, 114.5) | 7.0 (0.0, 232.5) | 8.5 (0.0, 143.0) | 16.5 (0.0, 209.5) | 8.5 (0.0, 201.0) | 7.5 (0.0, 97.0) | 7.0 (0.0, 144.0) | 8.5 (0.0, 161.5) | 9.0 (0.0, 107.0) |
Data are expressed as median (min, max), unless otherwise stated.
ABA, abatacept; ADA, adalimumab; CCP2, cyclic citrullinated peptide-2; CRP, C reactive protein; DAS28, Disease Activity Score 28; HAQ-DI, Health Assessment Questionnaire Disability Index; MTX, methotrexate; Q, quartile; RF, rheumatoid factor.